Summary: Warfarin-induced bleeding complications and high inter-patient variability are major hindrances to oral anticoagulant therapy. The present study identifies the influence of VKORC1 diplotypes, CYP2C9 and CYP2C19 variants on warfarin disposition and dose requirements in Chinese patients (n＝107). The study subjects were genotyped for VKORC1, CYP2C9 and CYP2C19 polymorphic variants. Weekly warfarin dose requirements and S-warfarin clearance were stratified by VKORC1, CYP2C9 and CYP2C19 pharmacogenetics. The major VKORC1 diplotypes were H1-H1 (62%), H1-H7 (18%) and H1-H * b (10%). Warfarin dose requirements were significantly lower in patients with VKORC1 H1-H1 and H1-H*a diplotypes compared to patients harboring the H1-H7 and H1-H * b diplotypes (Pº0.05). Hepatic tissues with H1-H1 diplotype had significantly lower expression of VKORC1 mRNA compared with liver tissues carrying the H1-H7 and H1-H*b diplotypes (P＝0.006). The percent variability explained by VKORC1 diplotype status was 59.1% while the CYP2C9 genotype status accounted for 6.9% variability in warfarin dose requirements. Patient age and weight were significant covariates accounting for 29% and 8.6% of warfarin dose variability, respectively. The present study shows that VKORC1 diplotype status, CYP2C9 genotype, age and weight are significant covariates, accounting for 73.4% of interindividual variability in warfarin dose requirements among Chinese patients. Translation of these findings into clinical guidelines for warfarin dosing may be required to assess its impact on the safety and efficacy of warfarin.
Introduction
Warfarin is the most common oral anticoagulant used worldwide for the treatment of short-and long-term thromboembolic disorders such as stroke, myocardial infarction, atrial fibrillation and deep vein thrombosis. 1, 2) Optimization of warfarin dose is clinically challenging due to its narrow therapeutic index and potential to cause serious bleeding complications. Wide inter-and intra-patient variability is also observed in warfarin dose requirements and the risk of warfarin-induced adverse effects. Factors including age, body weight, consumption of vitamin-K containing food supplements, drug interactions, ethnicity and genetic background of the patients have been identified and proposed to contribute to this phenomenon. [3] [4] [5] [6] [7] [8] Warfarin exists as a racemic mixture of R-and S-enantiomers. The pharmacologically active S-enantiomer is three to five times more potent than the R-form and accounts for almost 70% of overall anticoagulant activity. [9] [10] In humans, the disposition pathways of Rand S-warfarin are different, exhibiting both stereoselec- tive and regioselective metabolism. S-warfarin is predominantly metabolized by CYP2C9 to form the 7-hydroxylated form whereas R-warfarin is mainly metabolized by CYP1A1, CYP1A2, CYP3A4 and CYP2C19 to form the 6-, 8-and 10-hydroxylated metabolites of warfarin. S-warfarin also has a higher clearance and shorter elimination half-life compared with R-warfarin (0.31 vs 0.51 L/h/70 kg and 24 vs 40 hrs, respectively). 9) These pharmacokinetic differences between the two enantiomeric forms result in higher steady-state levels of Rwarfarin compared with the more active S-warfarin. 9, 11) Recent findings suggest that polymorphisms in the CYP2C9 and vitamin K epoxide reductase complex subunit 1 (VKORC1) genes significantly influence the pharmacokinetics and pharmacodynamics of warfarin. 12) The CYP2C9 enzyme catalyzes the metabolism of approximately 80% of active S-warfarin and its activity differs according to genotype status of the individual. Patients harboring CYP2C9*2 (Arg144Cys) and CYP2C9*3 (Ile359Leu) variants are associated with impaired metabolic capacity and require lower therapeutic doses of warfarin compared with patients harboring the reference CYP2C9*1 allele. [13] [14] [15] The risk of bleeding complications has been observed higher in patients carrying the CYP2C9*2 and *3 variants. [15] [16] The frequencies of the CYP2C9*2 and *3 alleles vary across ethnic groups and are reported highest in Caucasians (12% for CYP2C9*2 and 8% for CYP2C9*3), low in Blacks (1% to 3%) and rare in Asians (º1%). (13, (17) (18) (19) However, the impact of CYP2C9 genetic variants in the interpatient variability of warfarin doses is less pronounced than expected by their effects on warfarin metabolism, as determined by in-vitro enzymatic studies or in-vivo pharmacokinetic studies. 13, [19] [20] These findings suggest that additional polymorphic variants in genes involved in the warfarin biochemical pathway may be responsible for the wide differences in warfarin dose requirements among patients.
VKORC1 was recently discovered to be the target of warfarin and is involved in catalyzing the regeneration of the reduced hydroquinone form of vitamin K1 (vitamin K1H2) from its oxidized form. [21] [22] The reduced vitamin K1H2 is an essential cofactor required for the post-translational g-carboxylation of glutamic acid residues on clotting factors II, VII, IX and X and proteins C, S and Z. Studies have identified several high frequency polymorphisms in the VKORC1 gene that are ethnic dependent and which demonstrate gene-dose effects on warfarin dose requirements. 20, [23] [24] [25] [26] Rieder et al. 20) showed five strongly linked tag SNPs [381TÀC(rs7196161), 3673G ÀA(rs9923231), 6484CÀT(rs9934438), 6853CÀG (rs8050984) and 7566CÀT(rs2359612)] which were shown to be highly predictive of differentiating VKORC1 haplotypes associated with low-dose (H1 and H2) and high-dose (H7, H8 or H9) warfarin. Subsequent studies on other ethnic populations also show these VKORC1 haplotypes to be associated with warfarin sensitivity across different ethnic populations. [23] [24] [25] [26] [27] Both genotypes and diplotypes are representative of types of chromosome pairs in each individual. It is hypothesized that VKORC1 diplotypes may better explain the contribution of genetic variability to phenotypes. The present study investigates the impact of VKORC1 diplotypes and CYP2C9 and CYP2C19 polymorphisms on the variability of warfarin dose requirements and disposition in Chinese patients.
Methods
Patients: Chinese patients (n＝107) receiving anticoagulant therapy with warfarin at the Singapore General Hospital were prospectively recruited for study after obtaining prior informed consent. All patients were required to be on a stable maintenance dose of warfarin for at least one month with their international normalized ratio (INR) maintained between 2.0 and 3.0 without bleeding episodes. Patients with congestive heart failure (NYHA class 3 or greater), liver cirrhosis, thyroid disease or chronic gastrointestinal conditions were excluded from the study. Patients taking concurrent medication with potential to interact with warfarin were also receiving simvastatin (n＝15) and omeprazole (n＝18). The study was approved by the ethics committee of the Singapore General hospital.
Pharmacogenetic analysis of VKORC1, CYP2C9 and CYP2C19 polymorphic variants: Screening for VKORC1 polymorphic variants [381TÀC(rs7196161), 861CÀA(rs17880887), 3673GÀA(rs9923231), 5808T ÀG(rs2884737), 6484CÀT(rs9934438), 6853CÀG (rs8050984), 7566CÀT(rs2359612) and 9041GÀA (rs7294)] was in accordance to previously published study by our group. 27 ) Table 1 lists the primers and conditions for performing polymerase chain reaction (PCR) for CYP2C9 ( *2 and *3 ) and CYP2C19 ( *2 and *3 ) polymorphic variants. VKORC1 haplotypes were constructed in sequential order from the 381TÀC(rs7196161), 861CÀA(rs17880887), 3673GÀA(rs9923231), 5808T ÀG(rs2884737), 6484CÀT(rs9934438), 6853CÀG (rs8050984), 7566CÀT(rs2359612) and 9041GÀA (rs7294) genotypes using expectation-maximization algorithm [HelixTree software (HelixTree } Genetics Analysis Software Golden Helix, Inc.)]. VKORC1 diplotypes were ranked according to expectation-maximization probability and redundancy was trimmed using a probability cutoff value of 0.5.
Pharmacokinetics of warfarin: R-and S-warfarin plasma levels were estimated by stereospecific normalphase high-performance liquid chromatography with fluorescence detection as previously described.
28)
The calibration curves were linear over the concentration ranges tested, i.e. 0.041-10 mg/mL for R-warfarin (r 2 ＝ 0.9992) and S-warfarin (r 2 ＝0.9992) in plasma. The coefficients of variation for the intraday and interday reproducibility were 9.10% and 6.67% for R-warfarin, 8.69% and 12.65% for S-warfarin, respectively. The oral clearance of total S-and R-warfarin at steady state was calculated using the equation: CLoral＝(D/2t)/(Css) where D denotes the daily warfarin dose, t denotes the dosing interval and Css denotes the steady-state total concentration of S-or R-warfarin. The ratio of total S-to R-warfarin plasma concentrations (S:R) was calculated to determine the index of the relative metabolic clearance of the S-versus R-enantiomer.
VKORC1 hepatic expression: Genotyping and hepatic mRNA expression studies on VKORC1 were performed using non-cancerous (healthy) liver tissues from Chinese cancer patients (n＝40) undergoing hepatectomy for metastasis from colonic primary malignancy. The liver tissues were certified to be free of malignant cells by pathological examination. Total RNA was extracted from the liver tissues using TRIzoL Reagent (Invitrogen Corporation). The primers used for amplification were: VKORC1: forward 5?-CTGGGACAGGACA-GCATCCT-3? and reverse 5?-GTGTCCGCAGGCAACCT AAC-3?; GAPDH: forward 5?-CTGAACGGGAAGCTTG-TCA-3? and reverse 5?-CCAGTGGACTCCACGACGTA -3?, respectively, and RT-PCR analyses was carried out by ABI prism 7000 Sequence Detection System (Applied Biosystems, CA).
Statistical analysis: The chi-square test was used to assess Hardy-Weinberg equilibrium. All pharmacokinetic parameters are represented as means±SD, unless otherwise stated. Pairwise comparisons between haplotype or diplotype classes were made using the Mann-Whitney or Kruskal-Wallis test. The level of significance was set as P ＝0.05 for all comparisons unless otherwise stated. Univariate linear regression analysis was performed to estimate the association of patient covariates to warfarin dose and S-warfarin clearance variability. The covariates included were age, gender, weight, height, concurrent medication with omeperazole or simvastatin and clinical condition (deep vein thrombosis, atrial fibrillation or prosthetic valve replacement). The significant covariates (Pº0.05) in the univariate analysis were included in the multivariate regression model. Goodness-of-fit of the regression models was assessed by R 2 and comparison of regression models with different levels of complexity was based on adjusted R 2 . Model validation was based on prediction error sum of squares (PRESS) and R 2 for prediction as described by Montgomery et al.
29)
All statistical analyses were performed using Stata (STATA statistical software v7.0, Stata Corp., USA) and estimation of diplotype analysis was done by HelixTree software (HelixTree } Genetics Analysis Software Golden Helix, Inc.).
Results
Patient demographics: Approximately 61% of the patients were males and median age, height and weight of the patients were 64 years (range: 31 to 87 years), 162 cm (range: 142.5 to 185 cm) and 62.7 kg (range: 36.2 to 100.5 kg), respectively. Indications for warfarin therapy included deep vein thrombosis (44%) and cardiovascular conditions (atrial fibrillation, mitral valve regurgitation, transient ischaemic attack and stroke), (56%).
CYP2C9 and CYP2C19 polymorphisms and pharmacokinetics of S-and R-warfarin: The genotype and allele frequencies of CYP2C9 (*2 and *3) and CYP2C19 ( *2 and *3 ) polymorphisms in the Chinese patients are indicated in Table 2 . The genotype frequencies of all the investigated polymorphisms conformed to Hardy-Weinberg equilibrium. Most of the patients were homozygous for the reference CYP2C9*1 allele (n＝97). Ten patients harboed CYP2C9*2 and *3 variant allele (CYP2C9*1/*2, n＝1; CYP2C9*1/*3, n＝7; CYP2C9*3/*3, n＝2) and none of the patients harbored the CYP2C9*2/*2 or CYP2C9*2/*3 variant genotypes. Owing to the small number of patients in the heterozygous genotypic group, the total number of patients was pooled into three groups for statistical analysis of pharmacokinetic parameters:
CYP2C9*1/*1 (reference group), CYP2C9*1/*2＋CYP2C9*1/*3 (group with *2 or *3 heterozygous variant allele) and CYP2C9*3/*3 (group with *3 homozygous variant alleles). The mean weekly warfarin maintenance dose was highest in patients harboring the reference genotype (25.0±11.4 mg/week) (Table 3). Pairwise comparisons showed mean weekly warfarin dose requirements, exposure to steady-state S-warfarin levels (Css), clearance of S-warfarin (CLsw) and the enantiomeric S:R ratio of warfarin concentrations to be significantly different for patients homozygous for the CYP2C9 reference allele and those harboring one polymorphic allele (CYP2C9*1/*1 vs CYP2C9*1/*2＋ CYP2C9*1/*3: weekly dose, 25.0±11.4 vs 15.5±5.4 mg/week, P＝0.01; Css, 0.22±0.1 vs 0.34±0.2 mg/mL, P ＝0.01; CLsw, 0.05±0.03 vs 0.02±0.01 mL/min/kg, Pº0.001; and S:R, 0.48±0.2 vs 0.84±0.20, Pº0.001), respectively ( Table 3) . Patients harboring the CYP2C9 reference genotype had 3-and 2-fold higher CLsw compared with patients harboring one and two polymorphic alleles, respectively. The plasma S:R ratio of warfarin concentration was approximately two-fold lower in patients homozygous for the reference genotype compared with patients harboring either one or two polymorphic alleles ( Table 3) . Approximately half the patients harbored the reference CYP2C19*1/*1 genotype (n＝50) and fifty-three patients carried one polymorphic allele (CYP2C19*1/*2: n＝39; CYP2C19*1/*3: n＝8; CYP2C19*2/*3: n＝6). Four patients were homozygous for the CYP2C19*2 allele whereas none of the patients was homozygous for the CYP2C19*3 allele. No significant differences were observed between various CYP2C19 genotypic groups and R-warfarin pharmacokinetics ( Table 3) .
VKORC1 polymorphisms and warfarin dose requirements: With regards to VKORC1 polymorphisms ( Table 2) ,
6484CÀT(rs9934438), 6853CÀG (rs8050984), 7566CÀT(rs2359612) and 9041GÀA (rs7294) variants were highly polymorphic in the Chinese patients. Pairwise analysis showed strong linkage disequilibrium between the following polymorphisms: 381TÀC(rs7196161) with all other SNPs except 5808T ÀG(rs2884737) (D?À0.9); 861CÀA(rs17880887) with 3673GÀA(rs9923231) and 6853CÀG(rs8050984), (D? À0.9); 3673GÀA(rs9923231) with 6853CÀG (rs8050984), 7566CÀT(rs2359612) and 9041GÀA (rs7294), (D?À0.9); 6484CÀT(rs9934438) with 6853CÀG(rs8050984), 7566CÀT(rs2359612) and 9041GÀA(rs7294) (D?＝0.8); 6853CÀG(rs8050984) with 7566CÀT(rs2359612) and 9041GÀA(rs7294), (D?À0.8); 7566CÀT(rs2359612) with 9041GÀA (rs7294), (D?＝0.9) (Fig. 1) .
A total of fifteen haplotypes was inferred based on linkage disequilibrium data. Haplotypes H1 (CCATTCTG) and H7 (TCGTCGCA) were the most frequent in the Chinese population and accounted for a cumulative frequency of approximately 88%. Two novel VKORC1 haplotype cohorts [H * a (6%) and H * b (6%)] were inferred in the Chinese patients. Sequence clustering based on a complete linkage algorithm revealed the following haplotypes within each novel haplotype group: H*a [CCATTCCG(0. . The 3673GÀA(rs9923231) SNP previously reported to be among tag SNPs discriminating H1 and H7 haplotypes was also observed to differentiate between H*a and H*b 
0001).
A total of 7 VKORC1 diplotype groups was inferred and of which H1-H1 (62%), H1-H7 (18%) and H1-H*b (10%) comprised the most common diplotypes. The overall warfarin dose requirements differed significantly between diplotype groups (Pº0.05). The weekly warfarin dose requirements in patients harboring the H1-H1 and H1-H*a diplotypes were significantly lower compared to patients harboring the H1-H7 and H1-H * b diplotypes after adjustment with the bonferroni correction factor (H1-H1 vs H1-H7; 18.8±6.1 vs 35.9±11.3 mg/week, Pº0.0001; H1-H1 vs H1-H*b; 18.8±6.1 vs 38.3±6.3 mg/week, Pº0.0001) (Fig. 3A) . The significant differences in weekly warfarin dose requirements for low-(H1-H1 and H1-H*a) and high-dose (H1-H7 and H1-H*b) diplotypic groups were found to persist when analysis was restricted to patients homozygous for the reference CYP2C9*1 allele (Fig. 3B) .
VKORC1 mRNA expression in healthy liver tissues was Fig. 4; P＝0.002 ). Pairwise analysis, following adjustment for multiple comparison, revealed that hepatic VKORC1 mRNA expression was significantly lower in tissues harbouring H1-H1 and H1-H*a diplotypes compared with those carrying H1-H7 diplotypes (H1-H1 vs H1-H7; 1.64±1.04 vs 3.16±1.5, P＝0.006 and H1-H*a vs H1-H7; 0.66±0.09 vs 3.16±1.5 P＝0.0061, respectively) (Fig. 4) . Mean hepatic mRNA levels of subjects with H1-H*b diplotypes were 1.51-and 3.78 fold higher than those with H1-H1 and H1-H * a diplotypes, respectively (H1-H*b vs H1-H1; 2.48±1.1 vs 1.64±1.04 and H1-H*b vs H1-H*a; 2.48±1.1 vs 0.66±0.09). Among low dose defining diplotypes (H1-H1 and H1-H*a), hepatic VKORC1 mRNA levels of H1-H1 diplotype cohort were 2.5 fold higher than hepatic tissues carrying the novel H1-H*a diplotype constitution (H1-H1 vs H1-H*a; 1.64 ±1.04 vs 0.66±0.09).
Influence of covariate factors on weekly warfarin dose requirements and clearance: Univariate analysis showed that VKORC1 diplotype status (Pº0.0001), CYP2C9 genotype status (P＝0.007), gender (P＝0.013), weight (P＝0.003), height (P＝0.009) and age (Pº0.0001) were significant cofactors influencing weekly warfarin dose requirements (Table 4A) . Males required significantly higher weekly maintenance doses of warfarin compared with female patients (26.4±11.8 mg/week vs 21.0±9.3 mg/week; P＝0.02). Patient VKORC1 diplotype status and age accounted for 59.1% and 29.0%, respectively, of the variability in the weekly warfarin dose requirement while CYP2C9 genotype status, for approximately 6.9% of the total variability in warfarin dose requirement. Multivariate analysis indicated VKORC1 diplotype status (Pº0.0001), CYP2C9 genotype status (Pº0.0001), age (Pº0.0001) and weight (P ＝0.019) to contribute significantly to overall variability in warfarin dose. Patient stratification based on age showed that the mean weekly warfarin maintenance dose was significantly higher in patients less than 60 years compared with patients above 60 years of age (30.7± 12.3 vs 19.8±7.5 mg/week respectively, Pº0.0001). CYP2C9 genotype status was observed to be a significant covariate (P＝0.002), contributing approximately 9% to the overall variability in S-warfarin clearance.
Warfarin dosing model based on VKORC1 diplotypes: Linear regression was used to identify the warfarin dosing model incorporating the significant covariates screened in the present study. The dosing model including VKORC1 diplotype status, CYP2C9 genotype status, age and weight accounted for 74.2% of the variance in weekly warfarin maintenance dose requirements ( Table  3B) , the prediction based on PRESS was 53%.
Discussion
Warfarin disposition is complex, involving several factors such as diet, disease state, body weight, gender, comedications and also polymorphic genes across the warfarin biochemical pathway. 30) The large degree of interpatient variability in warfarin dose requirements and S-warfarin pharmacokinetics has been partly attributed to CYP2C9 polymorphisms. The impact of CYP2C9 genotypic status on pharmacokinetic and pharmacodynamic effects of warfarin and its dose requirements differ in patients of different ethnic backgrounds. [7] [8] [9] [10] [14] [15] [16] [17] Previous studies on warfarin pharmacogenetics in distinct ethnic groups of Chinese, Malay and Indians have mainly evaluated the influence of CYP2C9 genotypes on warfarin dose requirements but not on S-warfarin pharmacokinetics. 19) In the present study, Chinese patients harboring the CYP2C9 reference genotype had higher S-warfarin clearance and required higher weekly warfarin doses compared with patients harboring one or two CYP2C9 polymorphic alleles. Patients with CYP2C9 polymorphic alleles (*2 or *3) required approximately 38% and 44% less weekly warfarin doses compared to patients harboring the reference allele. The significantly lower plasma warfarin S:R ratio in patients homozygous for the reference CYP2C9 allele compared with patients harboring one or two polymorphic alleles suggests a higher metabolic capacity associated with the CYP2C9*1 allele towards the S-enantiomer ( Table 2) . However, the contribution of CYP2C9 genetic polymorphisms to overall interindividual variability in warfarin dose requirements was approximately 6.9%, similar to the observations reported in Hong Kong Chinese population (7.9%). 30) Possible reasons for the limited influence of CYP2C9 genotypic status on warfarin doses may be the low frequencies of defective CYP2C9*2 or *3 alleles in the Chinese population compared to Caucasian populations. 31) No genotypic influence of CYP2C19 polymorphisms was observed with regard to R-warfarin clearance ( Table 3 ) and this reflects the multiplicity of cytochrome P450 enzymes involved in catalyzing the metabolism of the R-enantiomer.
8)
The combined genotypic effects of CYP2C9 and CYP2C19 polymorphisms on warfarin pharmacokinetics failed to reveal any significant findings. (Data not shown) .
Functional polymorphic variants in the gene encoding VKORC1 have been shown associated with decreased catalytic activity of the enzyme and also with warfarin dose requirements in different populations. 20, [23] [24] [25] [26] 32) Similar to earlier reports on VKORC1 haplotypes in other ethnic groups including Asians, 4, 26, [30] [31] [32] [33] the present study shows that 78% of Chinese patients harbor the low-dose (H1) haplotype and 10% of the patients harbored high dose (H7) haplotype. Taken together, these results suggest that most Chinese patients require significantly lower warfarin maintenance doses compared with other populations to achieve similar degree of anticoagulation. 5, 31) This could be attributed to the high frequency of low warfarin dose associated VKORC1 variant alleles [381TÀC(rs7196161), 0.85; 3673GÀA(rs9923231), 0.84; and 6484CÀT(rs9934438), 0.83] and the high frequency of the 6853CÀG(rs8050984) (0.86) reference allele in the Chinese population.
Novel haplotypes identified in the present study had unique genomic sequences, in which all H*a haplotypes preserved the A allele at position 3673GÀA(rs9923231) as observed in patients carrying the H1 haplotype constitution. Patients carrying H*b haplotypes were found to preserve the G allele at position 3673GÀA(rs9923231), which is similar to that observed in patients carrying the H7 haplotype constitution. VKORC1 hepatic expression analysis showed significant association with 3673GÀA (rs9923231), thus corroborating the influence of the VKORC1 genotypic constitution and VKORC1 activity involved in mediating the anticoagulation pathway and warfarin dose requirements.
Previous studies on Asian populations did not address the phenotypic influence of critical VKORC1 polymorphisms which segregated low-and high-dose defining VKORC1 haplotypes. 20, [31] [32] [33] [34] [35] [36] [37] [38] [39] The primary polymorphic candidates that may explain this effect would be those designating the major haplotype split at 381TÀC (rs7196161), 3673GÀA(rs9923231), 6484CÀT (rs9934438) and 6853CÀG(rs8050984). 20) However, these polymorphisms are in strong linkage disequilibrium and it is impossible to evaluate the role of each polymorphism separately. Although haplotypes are representatives of single-locus alleles, a diplotype is representative of a subset of every single-locus genotype. Thus, under Hardy-Weinberg disequilibrium, diplotype-based analysis may be more informative than haplotypewise analysis, and better correlated with clinical and pharmacokinetic characteristics. [40] [41] [42] In the present study, although 84% of patients were associated with low dose defining haplotypes (H1 and H*a), the diplotype-based approach revealed that only 65% of Chinese patients belonged to the low dose group. Chinese patients harboring the H1-H7 and H1-H * b diplotypes required significantly higher doses of warfarin compared with H1-H1 and H1-H*a groups (Pº0.01, Fig. 3A) . These significant variations in warfarin dose requirements among the diplotypic groups were preserved only for patients homozygous for the CYP2C9 reference genotype (Fig. 3B) .
The study also shows that a dosing model incorporating the VKORC1 diplotypes explains the significantly higher variability in warfarin dose requirements (74.2%), which was significantly higher compared to previously published studies (R 2 ＝25% to 65%). 23, 26, 43) Furthermore, the predicted residuals in the VKORC1 diplotype based algorithm showed that 67% of the patients were in the acceptable dosing range (-7 to 3.5 mg/week) and the median residual dose was -0.04. The frequency of predicted doses in the acceptable dosing range was also considerably higher than previous studies by Sconce et al. 26) and Tham et al. 43) The finding that non-genetic factors such as age was a significant contributor to variability in warfarin dose requirements in the Chinese patients (Table 3 ) supports the observation of increased sensitivity to warfarin in elderly patients. Although the exact mechanism for this observation remains unknown, 44) similar findings by other groups 45) strongly suggest that in addition to genetic factors, patient age should also be taken into account when adjusting for patient warfarin dosage. Our study did not observe significant effect of age which has been reported an independent variable influencing S-warfarin clearance. [46] [47] S-warfarin clearance is mediated primarily by the CYP2C9 enzyme and most subjects (91%) in the present study were CYP2C9 extensive metabolisers (*1/*1). The effect of age is probably masked by the influence of CYP2C9 genotype status of the subject in the present study. There was no significant influence of comedication such as simvastatin and omeprazole on warfarin dose requirements in the present study. This could probably be attributed to the small number of patients receiving concurrent medications along with simvastatin and omeprazole (N＝33).
Conclusion
This study provides new insights regarding the contributions of genetic and non-genetic factors on warfarin dose requirements in Chinese patients. VKORC1 diplotype status and age were found important determinants of weekly warfarin maintenance dose and the VKORC1 diplotypes were better able to stratify the patients into low-and high-dose warfarin groups. The diplotype-based approach was found to explain better interpatient variability in warfarin dose requirements and future studies should evaluate this model for safety and efficacy of warfarin dosing in other Asian and non-Asian ethnic groups.
